Variability in renal clearance of substrates for renal transporters in Chinese subjects

Journal of Clinical Pharmacology

Volumn 46, Issue 2, 2006, Pages 157-163

  Yin, Ophelia Q P ^a   Tomlinson, Brian ^a   Chow, Moses S S ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Genetic variability; Renal clearance; Renal transporters

Indexed keywords

AMPICILLIN; CEFALEXIN; CIMETIDINE; FAMOTIDINE; METFORMIN; ORGANIC ANION TRANSPORTER;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; DRUG URINE LEVEL; ETHNIC GROUP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NORMAL HUMAN; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALGORITHMS; AMPICILLIN; AREA UNDER CURVE; CARRIER PROTEINS; CEPHALEXIN; CHINA; FAMOTIDINE; FEMALE; HUMANS; KIDNEY; MALE; METFORMIN; ORGANIC ANION TRANSPORTERS; ORGANIC CATION TRANSPORT PROTEINS;

EID: 31344468048     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270005283838     Document Type: Article

References (29)

1. Leabman MK, Giacomini KM. Estimating the contribution of genes and environment to variation in renal drug clearance. Pharmacogenetics. 2003;13:581-584.
2. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparison of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics. 1998;8:283-289.
3. Kalow W, Endrenyi L, Tang BK. Repeat administration of drugs as a means to assess the genetic component in pharmacological variability. Pharmacology. 1999;58:281-284.
4. Akhtar MJ, Khan S, Khan MAS. Determination of ampicillin in human plasma by high-performance liquid chromatography using ultraviolet detection. J Pharm Biomed Anal. 1993;11:375-378.
5. Kovach PM, Lantz RJ, Rrier G. High-performance liquid chromatographic determination of loracarbef, a potential metabolite, cefaclor and cephalexin in human plasma, serum and urine. J Chromatogr. 1991;567:129-139.
6. Dowling TC, Frye RF. Determination of famotidine in human plasma and urine by high-performance liquid chromatography. J Chromatogr. 1999;732:239-243.
7. Vincek WC, Constanzer ML, Hessey GA II, Bayne WF. Analytical method for the quantification of famotidine, an H2-receptor blocker, in plasma and urine. J Chromatogr. 1985;338:438-443.
8. Cheng CL, Chou CH. Determination of metformin in human plasma by high-performance liquid chromatography with spectrophotometric detection. J Chromatogr. 2001;762:51-58.
9. Hampel B, Lode H, Bruckner G, Koeppe P. Comparative pharmacokinetics of sulbactam/ampicillin and clavulanic acid/amoxycillin in human volunteers. Drugs. 1988;35:29-33.
10. Barbhaiya RH. A pharmacokinetic comparison of cefadroxil and cephalexin after administration of 250, 500 and 1000 mg solution doses. Biopharm Drug Dispos. 1996;17:319-330.
11. Yeh KC, Chremos AN, Lin JH, et al. Single-dose pharmacokinetics and bioavailability of famotidine in man: results of multicenter collaborative studies. Biopharm Drug Dispos. 1987;8:549-560.
12. Tucker GT, Casey C, Phillips PJ, et al. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981;12:235-246.
13. Glomerular filtration. In: Massry SG, Glassock RJ, eds. Massry & Glassock's Textbook of Nephrology. 4th ed. Philadelphia, Pa: Lippincott William & Wilkins; 1995:56-64.
14. Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H. Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem. 1997;272:18526-18529.
15. Takeda M, Babu E, Narikawa S, Endou H. Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Clin Pharmacol. 2002;438:137-142.
16. Terada T, Saito H, Mukai M, Inui K. Recognition of beta-lactam antibiotics by rat peptide transporters PEPT1 and PEPT2, in LLC-PK1 cells. Am J Physiol. 1997;273:F706-F711.
17. Terada T, Saito H, Mukai M, Inui K. Characterization of stably transfected kidney epithelial cell line expressing rat H+/peptide cotransporter PEPT1: localization of PEPT1 and transport of beta-lactam antibiotics. J Pharmcol Exp Ther. 1997;281:1415-1421.
18. Dresser MJ, Xiao G, Leabman MK, Gray AT, Giacomini KM. Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2). Pharm Res. 2002;22:562-567.
19. Kimura N, Okuda M, Inui K. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm Res. 2005;22:255-259.
20. Lin JH, Los LE, Ulm EH, Duggan DE. Kinetic studies on the competition between famotidine and cimetidine in rats. Drug Metab Dispos. 1988;16:52-56.
21. Inotsume N, Nishimura M, Nakano M, Fujiyama S, Sato T. The inhibitory effect of probebecid on renal excretion of famotidine in young, healthy volunteers. J Clin Pharmacol. 1990;30:50-56.
22. Bahn A, Prawitt D, Buttler D, Reid G, Enklaar T. Genomic structure and in vivo expression of the human organic anion transporter 1 (hOAT1) gene. Biochem Biophys Res Commun. 2000;275:623-630.
23. Bahn A, Ebbinghaus C, Ebbinghaus D, et al. Expression studies and functional characterization on renal human organic anion transporter 1 isoforms. Drug Metab Dispos. 2004;32:424-430.
24. Leabman MK, Huang CC, Kawamoto M, et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics. 2002;12:395-405.
25. +/peptide cotransporter 2 causes a complete loss of transport function. Biochem Biophys Res Commun. 2004;316:416-420.
26. +/dipeptide transporter PEPT2: analysis of haplotype functions. J Pharm Exp Ther. 2004;311:1088-1096.
27. Haginaka J, Wakai J. Liquid chromatographic determination of ampicillin and its metabolites in human urine by postcolumn alkaline degradation. J Pharm Pharmacol. 1987;39:5-8.
28. Kroemer H, Klotz U. Pharmacokinetics of famotidine in man. Int J Clin Pharmacol Ther Toxicol. 1987;25:458-463.
29. Hunter DJ, Lange M, Snieder H, et al. Genetic contribution to renal function and electrolyte balance: a twin study. Clin Sci. 2002;103:259-265.